Select Language
IL23A & IL12B
IL23A & IL12B Overview
| English Name | Interleukin-12 subunit beta | Approved Drugs | 8 |
| Drugs in Clinical Trials | 2 | Target Synonym | IL-12B，NK cell stimulatory factor chain 2，IL12B，Interleukin 12B，Interleukin 12B (Natural Killer Cell Stimulatory Factor 2， Cytotoxic Lymphocyte Maturation Factor 2， P40)，Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit，Interleukin-12 Beta Chain，Interleukin 12， P40，IL12， Subunit P40，CLMF P40，NKSF2，Cytotoxic Lymphocyte Maturation Factor 2， P40，Interleukin-12 Subunit Beta，CLMF2，IMD28，IMD29，CLMF，NKSF，Interleukin-12 Subunit p40，Natural Killer Cell Stimulatory Factor， 40 KD Subunit，IL-12 Subunit P40，Natural Killer Cell Stimulatory Factor-2 |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-12 subunit beta |
| Target Synonym | IL-12B，NK cell stimulatory factor chain 2，IL12B，Interleukin 12B，Interleukin 12B (Natural Killer Cell Stimulatory Factor 2， Cytotoxic Lymphocyte Maturation Factor 2， P40)，Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit，Interleukin-12 Beta Chain，Interleukin 12， P40，IL12， Subunit P40，CLMF P40，NKSF2，Cytotoxic Lymphocyte Maturation Factor 2， P40，Interleukin-12 Subunit Beta，CLMF2，IMD28，IMD29，CLMF，NKSF，Interleukin-12 Subunit p40，Natural Killer Cell Stimulatory Factor， 40 KD Subunit，IL-12 Subunit P40，Natural Killer Cell Stimulatory Factor-2 |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 2 |
| Highest Development Stage | Approved |
IL23A & IL12B Product List
- Product Category
Protein (16)
- Product Status
Launched (16)
- Species
Human (3)Human & Mouse (1)Mouse (2)Cynomolgus & Mouse (1)Human & Rat (2)Cynomolgus (2)Rat (1)Rabbit (1)Human | Alpaca (1)Golden Hamster (1)Guinea pig (1)
- Tag
His Tag (12)His Tag & Avi Tag (3)Tag Free (1)
- Conjugate
Unconjugated (13)Biotin-labeled (3)
Add to Cart
Total: 16
- 1
- 2
IL23A & IL12B Background
Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.
IL23A & IL12B Synonyms
IL-23 alpha & IL-12 beta
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| RO-7837195 | RO-7837195; RO7837195 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative | Details |
| PF-07261271 | RG-6730; PF-07261271 | Phase 2 Clinical | Pfizer Inc | Inflammatory Bowel Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab biosimilar (Bio-Thera) | BAT-2206 | Approved | Bio-Thera Solutions Ltd | STARJEMZA, Usymro | United States | Plaque psoriasis; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | Bio-Thera Solutions Ltd | 2025-05-22 | Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Arthritis, Juvenile; Arthritis, Psoriatic; Colitis, Ulcerative; Common Variable Immunodeficiency; Crohn Disease; Dermatitis, Atopic; Dermatomyositis; Diabetes Mellitus, Type 1; Hidradenitis Suppurativa; Ichthyosis; Inflammatory Bowel Diseases; Liver Cirrhosis, Biliary; Lupus Erythematosus, Systemic; Multiple Sclerosis; Palmoplantar pustulosis; Pediatric Crohn's disease; Plaque psoriasis; Polymyositis; Pouchitis; Psoriasis; Sjogren's Syndrome; Spondylitis, Ankylosing; Takayasu Arteritis; Type I Leukocyte Adhesion Defect; Uveitis | Details |
| Ebdarokimab | AK-101; AK101 | Approved | 爱达罗 | Mainland China | Plaque psoriasis | Zhongshan Akeso Biopharma Co Ltd | 2025-04-15 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details | |
| Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV, Qoyvolma | Canada | Arthritis, Psoriatic; Crohn Disease; Plaque psoriasis | Celltrion Inc | 2024-08-01 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Biocon) | Bmab 1200 | Approved | Biocon Biologics Ltd | Yesintek | United States | Colitis, Ulcerative; Crohn Disease; Arthritis, Psoriatic | Biocon Biologics Inc | 2024-11-29 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva, Eksunbi | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Diseases; Inflammation; Plaque psoriasis; Psoriasis; Rheumatic Diseases; Skin Diseases | Details |
| Ustekinumab biosimilar (Amgen) | ABP-654; AMG-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla, WEZENLA | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland